---
title: "What is HC Wainwright's Estimate for Cybin FY2029 Earnings?"
description: "HC Wainwright has revised its FY2029 earnings per share (EPS) estimate for Cybin Inc. (NYSE:CYBN) from $9.57 to $8.87, maintaining a \"Buy\" rating with a target price of $190.00. The consensus estimate"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/226657389.md"
published_at: "2025-01-30T07:19:05.000Z"
---

# What is HC Wainwright's Estimate for Cybin FY2029 Earnings?

> HC Wainwright has revised its FY2029 earnings per share (EPS) estimate for Cybin Inc. (NYSE:CYBN) from $9.57 to $8.87, maintaining a "Buy" rating with a target price of $190.00. The consensus estimate for Cybin's current full-year earnings is ($4.88) per share. Canaccord Genuity also lowered its price target for Cybin from $96.00 to $86.00. Cybin is a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics for mental health conditions.

Cybin Inc. (NYSE:CYBN - Free Report) - Analysts at HC Wainwright dropped their FY2029 earnings per share (EPS) estimates for Cybin in a research note issued to investors on Monday, January 27th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of $8.87 for the year, down from their prior estimate of $9.57. HC Wainwright currently has a "Buy" rating and a $190.00 target price on the stock. The consensus estimate for Cybin's current full-year earnings is ($4.88) per share.

Separately, Canaccord Genuity Group decreased their price objective on Cybin from $96.00 to $86.00 and set a "buy" rating for the company in a research note on Thursday, November 14th.

**Check Out Our Latest Report on CYBN**

## Cybin Stock Performance

Shares of CYBN stock opened at $9.86 on Wednesday. The stock has a 50-day moving average price of $9.78. The firm has a market capitalization of $197.83 million, a price-to-earnings ratio of -1.48 and a beta of 0.44. Cybin has a 12 month low of $6.50 and a 12 month high of $19.85.

## Hedge Funds Weigh In On Cybin

An institutional investor recently bought a new position in Cybin stock. Sanctuary Advisors LLC acquired a new stake in Cybin Inc. (NYSE:CYBN - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 131,252 shares of the company's stock, valued at approximately $36,000. Hedge funds and other institutional investors own 17.94% of the company's stock.

## About Cybin

(Get Free Report)

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.

## Featured Stories

-   Five stocks we like better than Cybin
-   What Do S&P 500 Stocks Tell Investors About the Market?
-   How to Short Sell Stocks Like a Pro: Strategies and Tips
-   REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today
-   3 Steel Stocks Soaring After Tariff Announcements
-   How to Read Stock Charts for Beginners
-   Top Analysts’ Picks for 2025: 3 of Morgan Stanley's Favorites

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

## Should You Invest $1,000 in Cybin Right Now?

Before you consider Cybin, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.

While Cybin currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [CYBN.US - Cybin](https://longbridge.com/en/quote/CYBN.US.md)
- [HELP.US - Cybin](https://longbridge.com/en/quote/HELP.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Cybin Inc. Appoints Michael Cola as CEO | Cybin Inc. has appointed Michael Cola as CEO, effective immediately. Cola has over 30 years of experience in neuroscienc | [Link](https://longbridge.com/en/news/275610173.md) |
| Helus Pharma Names Michael Cola as Chief Executive Officer | Cybin Inc. has appointed Michael Cola as Chief Executive Officer of Helus Pharma. Cola has over 30 years of experience i | [Link](https://longbridge.com/en/news/275457778.md) |
| Cybin Inc. Showcases Breakthrough Serotonergic Drug Pipeline for Depression and Anxiety | Cybin Inc. has unveiled its advancements in serotonergic drug development for mental health, focusing on HLP003 and HLP0 | [Link](https://longbridge.com/en/news/271690452.md) |
| Cybin Initiates At-The-Market Equity Program of up to US$100 Million \| CYBN Stock News | Cybin Inc. has launched an at-the-market equity program allowing the issuance and sale of up to US$100 million of common | [Link](https://longbridge.com/en/news/271139085.md) |
| Cybin Launches US$100 Million At-the-Market Equity Program | Cybin Inc. has launched a US$100 million at-the-market equity program to issue and sell common shares through Cantor Fit | [Link](https://longbridge.com/en/news/271242962.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
